We aimed to evaluate in a phase I dose-escalation study, the safety of intramuscular injections of a novel non-viral plasmid DNA expressing two isoforms of human hepatocyte growth factor (HGF) (VM202) in patients with critical limb ischemia (CLI). In total, 12 patients with CLI and unsuitable for revascularization were consecutively assigned to increasing doses (2 to 16 mg) of VM202 administered into the ischemic calf muscle at days 1 and 15. Patients were evaluated for safety and tolerability, changes in ankle-and toe brachial index (ABI and TBI), and pain severity score using a visual analog scale (VAS) throughout a 12-month follow-up period. Median age was 72 years and 53% of the patients were male. VM202 was safe and well tolerated with no death during the 12-month follow-up. Median ABI and TBI significantly increased from 0.35 to 0.52 (P¼0.005) and from 0.15 to 0.24 (P¼0.01) at 12 months follow-up. Median VAS decreased from 57.5 to 16.0 mm at 6 months follow-up (P¼0.03). In this first human clinical trial, VM202, which expresses two isoforms of human HGF, appear to be safe and well tolerated with encouraging clinical results and thus supports the performance of a phase II randomized controlled trial.
INTRODUCTION
Critical limb ischemia (CLI) represents the most advanced stage of lower extremity peripheral artery disease, and ischemic amputation is its most devastating limb outcome. The incidence of CLI is increasing and occurs in up to 250 000 Americans per year. 1 A recent population study estimated the incidence of CLI to be 340 per million per year 2 and ischemic amputation was 188 per 100 000 Medicare beneficiaries in 2006. 3 The 1-year mortality rate of patients with CLI is 25% and may be as high as 45% in those who have undergone amputation. 4, 5 As there are currently few effective pharmacological therapies available for CLI, treatment consists primarily of revascularization or lower extremity amputation. 4, 6 Therapeutic angiogenesis, either as recombinant protein, gene transfer or stem cell therapy, delivered to the ischemic muscle, has shown promising results and provides hope for CLI patients who are unsuitable candidates for revascularization. 7, 8 Recent randomized controlled trials of vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGF) have demonstrated excellent safety and significant clinical improvement including beneficial hemodynamic effects and a reduction in death and major amputation. 9, 10 In addition, a phase II, placebo-controlled trial using a single isoform of hepatocyte growth factor (HGF), an angiogenic protein that regulates multiple genes involved in the angiogenic process in patients with CLI, demonstrated excellent safety with an increase in transcutaneous oxygen tension (TCPO 2 ) in the high-dose group, thus providing evidence for its bioactivity. 11 VM202, a DNA plasmid that contains a novel genomic cDNA hybrid of human hgf gene expressing two wild-type isoforms of HGF (pCK-HGF-X7), has been shown in porcine myocardial infarction models to improve myocardial perfusion and left-ventricular function, 12, 13 as well as increased capillaries, improved myocardial viability and left-ventricular function compared with control animals. 14 Moreover, in a rabbit hindlimb model, investigators found that co-expression of both isoforms of HGF could more efficiently induce the migration of HUVEC and C 2 C 12 myoblasts than VEGF 165 or single isoform of HGF. 15 However, the safety and efficacy of the dual isoforms of HGF have not yet been studied in humans.
The primary purpose of this first human phase I, dose-escalation study was to assess the safety and tolerability of intramuscular VM202 in patients with CLI who were not suitable for lower extremity revascularization. The secondary objective was to evaluate the bioactivity of VM202 on improved arterial perfusion. March 2007 and October 2008, 22 patients with CLI and not  suitable for revascularization procedures were screened and 15 were consented and enrolled in the study. Three patients were withdrawn from the study before the treatment for the following reasons: an ankle pressure above the inclusion criteria, unstable angina and an ulcer, which healed before baseline injection in a patient without rest pain. A total of 12 patients were treated with VM202 with follow-up safety and efficacy data available for all patients at 3, 6 and 12 months, except for 1 patient with below the knee amputation in which efficacy data was not applicable at 6 and 12 months follow-up. The median age was 71.5 years (interquartile range 61.5, 76.5) and 58.3% were male patients. As expected, a high proportion of patients had hypercholesterolemia, hypertension and were former or current smokers. The total number of endovascular procedures performed before enrollment for all patients was 37 with an average of 3.1 procedures per patients. The total number of open arterial surgical procedures for these patients was 21 with an average of 1.8 surgical procedures per patient. Detailed subject demographics are shown in Table 1 and treatment groups were well-balanced at baseline. At baseline, 10 (83.3%) of 12 patients were on narcotic and 2 were on non-steroidal anti-inflammatory pain medication. At 6 months follow-up, four patients stopped narcotic pain medication and remained off narcotics for the remainder of the study.
RESULTS

Between
Safety analysis
Intramuscular injection of VM202 in the ischemic calf muscle was well tolerated at doses as high as 16 mg. Severe complications and adverse effects caused by gene transfer were not detected in any patients. Of particular importance, no apparent edema was observed in any patients throughout the trial. There were no signs of systemic or local inflammatory reactions throughout the gene therapy periods. No coronary events or progression of diabetic retinopathy were observed in any patients transfected with VM202. Overall, a total of 10 serious adverse events occurred in six patients (50.0%). No death was observed during the study. One major below-knee amputation occurred in a 72-year-old male patient at 6 months because of progression of non-healing ulcers with bone exposure, osteomyelitis and uncontrolled pain on oral pain medication. Detailed incidents of serious adverse events are given in Table 2 .
Two patients developed malignant neoplasia detected during follow-up visits. One malignant lung neoplasia occurred in an 84-yearold female patient, in the 2 mg-dose cohort, who was noted to have a right lower lung mass and masses on the right and left lobe of the liver on scheduled computed tomography scan of the chest at routine 12 months follow-up. Tumor marker and biopsy of the liver mass revealed lung cancer with liver metastasis. All tumor markers measured at 6 months follow-up for this patient were within the normal range. VM202 levels in serum samples were below the detection limit at 6 days after the second dosing and at all subsequent follow-up visits. In a biopsy of the liver mass, no VM202 could be detected. However, lack of VM202 does not rule out the possible direct or indirect involvement of pCK-HGF-X7 in tumor development. The second patient, an 80-year-old female in the 8-mg dose cohort, developed localized adenocarcinoma of the colon, which was detected at 6 months follow-up routine endoscopy and was successfully treated with laparoscopic hemicolectomy. No biopsy sample of the tumor was available to investigate the relationship of gene expression of VM202. Thus, the relation to VM202 is unknown.
With the exception of one patient who had 2416 copies (limit of quantitation is 2000 copies), VM202 was not detectable in the peripheral circulation at 2 months follow-up. HGF protein levels remained stable throughout the study without any peak post-injections. In fact, there was a slight decrease from baseline on days 8, 15 and 21, which likely represents normal variability. At no time was antibody formation to HGF protein detected in the blood (Table 3) . Only one patient experienced a minor injection site reaction at day 1, which resolved by day 8, otherwise all the injections were well tolerated in all the patients.
Efficacy results
Median ankle brachial index (ABI) significantly increased from 0.35 to 0.45 (P¼0.015) at 3 months, to 0.49 (P¼0.014) at 6 months and to 0.52 (P¼0.005) at 12-month follow-up compared with baseline. ABI from baseline through follow-up for all four cohorts is shown in Figure 1 . The median toe brachial index (TBI) at 3 and 6 months was increased (0.20 and 0.22, respectively); this physiological outcome reached statistical significance at 12 months (0.15 to 0.24, P¼0.012; Figure 1 ).
The median value of TCPO 2 showed a positive trend from 38.5 to 42 and 46 mm Hg at 6 and 12 months follow-up, respectively, but did not reach statistical significance. Overall, TCPO 2 measurement was highly variable throughout the study and these data are shown by cohort in Figure 2 .
Overall, 9 of 11 patients experienced pain reduction at 6 months follow-up and median visual analog scale (VAS) decreased from 57.5 mm at baseline to 16.0 mm (P¼0.03) at 6 months follow-up. Although the median VAS was also decreased at 3 and 12 months follow-up (38.5 and 44.0 mm, respectively), this score did not reach statistical significance. A net reduction in pain severity was reported in 7 of 11 patients (63.6%) at 12 months follow-up. The 4-mg dose cohort experience the greatest reduction in pain with an average net reduction of 61.67 mm on the VAS scale ( Figure 3 ). The second cohort that experienced a substantial average net pain reduction of 20.7 mm was the 2-mg cohort group. Three patients, in both the 2-and 4-mg dose cohort, who experienced net pain improvement, had diabetes or neuropathy, possibly suggesting some benefit of VM202 in this sub-population. Overall, 13 ulcers were measured and tracked in 8 patients at baseline. Out of 13 ulcers (15%), 2 disappeared at 1 month after first VM202 treatment (15 days after second VM202 treatment). As shown in Figure 4 , 9 (69%) out of 13 ulcers were completely healed and remained healed until the end of the study (P¼0.015). Overall, 7 (88%) out of 8 patients with ulcers noted a net decrease in ulcer size from baseline or time of first onset to the end of the study.
DISCUSSION
This prospective phase I dose-escalation evaluation is the first clinical study to assess the safety and tolerability of VM202, which expresses two isoforms of HGF in humans. Circulating HGF protein levels remained relatively constant throughout the study, suggesting that the plasmid remained active only at the injection site. VM202 does not appear to be immunogenic, as evidenced by the lack of antibody formation of HGF in our study. There were no deaths and only one major amputation at 12 months follow-up. ABI and TBI significantly improved at follow-up. and 9 of 13 ulcers (69%) completely healed. Overall, 63.6% of all patients experienced a net pain reduction measured by VAS severity score at 12 months follow-up. Thus, hemodynamic and clinical efficacy are suggested by these data and they underscore the potential utility of this agent in patients with CLI. TCPO 2 did show a trend of improvement, but the values obtained during the study showed considerable variability, as is typical for this measure. 16, 17 Although this study was not powered to detect any significant improvement in efficacy measures, these results are encouraging. A phase II, randomized, placebo-controlled trial, which will assess the efficacy of VM202 in a larger cohort, has been approved by the Food and Drug Administration, and recruitment has begun in April 2010.
HGF is a mesenchymal-derived pleiotropic factor that regulates cell growth, cell motility and morphogenesis of various types of cells. HGF is also a powerful angiogenic growth factor and is secreted by vascular endothelial cells and smooth muscle cells. 18 It has been shown to activate the transcription factor Ets-1 through the c-Met receptor, thus, upregulating the expression of VEGF, matrix metalloproteinases and HGF. 19, 20 The mitogenic activity of HGF has been reported to be significantly more pronounced than that of VEGF in human aortic endothelial cells in vitro as well as a rabbit hindlimb ischemia model in vivo. 21, 22 Several randomized trials using other genes such as vegf or fgf have demonstrated excellent safety and tolerability, as well as increased biological markers, which indicate improved limb perfusion. 9, 23 The TALISMAN trial, which included 125 patients with CLI unsuitable for revascularization treated with NV1fibroblast growth factor versus placebo, demonstrated a significant improvement in the secondary outcome measures of all amputation, major amputation and the combination of major amputation and death in the treatment group. 10 Our findings are supported by a recent double-blind, placebocontrolled, multicenter trial of 104 patients receiving placebo or HGF plasmid (encoding single isoform) of 1.2, 8 or 12 mg in three dose cohort. 11 Five patients developed malignancy during the 12 months follow-up, of which two were in the placebo group and three in the intervention group. In addition, seven patients died during follow-up, two in the placebo group and five in the intervention group. 11 As noted above, patients treated with the higher dose had an improvement in TCPO 2 . Another single-center study of six patients with CLI reported no significant adverse effects and improvements in ABI by more than 0.1 in all patients and improvement in ulcer size by more than 25% in 8 of 11 ulcers. 24 Preclinical and clinical studies have shown only a local increase in HGF and no evidence of increase in malignancy rates. 24, 25 Two patients in this trial developed a Figure 1 Effect of plasmid DNA expressing two isoforms of HGF on ankle-and toe brachial index (ABI and TBI) in 12 subjects separated by cohort. ABI and TBI measurement at baseline and at 3, 6 and 12 months follow-up show overall an increase in all four dosing cohort (12 subjects). Of note, no ABI and TBI values were available at 6 and 12 months for one subject in cohort 3 because of major amputation and one ABI and TBI values at 12 months was not obtained due to pain from pressure cuff. The outlier in cohort 4 belongs to one subject with Buerger's disease who had more distal ischemia. * P¼0.015; baseline vs 3 months after VM202 injection, y P¼0.014; baseline vs 6 months after VM202 injection, w P¼0.005; baseline vs 12 months after VM202 injection, z P¼0.012; baseline vs 12 months after VM202 injection. Figure 2 Change in transcutaneous oxygen tension (TCPO 2 ) in 12 subjects after intramuscular VM202 injection separated by cohort. TCPO 2 shows high variation of measurement across the dosing cohort. Of note, no TCPO 2 value was available at 6 and 12 months for one subject in cohort 3 because of major amputation.
Dual Isoforms of HGF for CLI TD Henry et al malignancy during the 12-month follow-up period including metastatic lung cancer, which was not evident at 6 months, and a localized adenocarcinoma of the colon at 6 months follow-up, which was successfully resected. Although we are concerned about the development of cancer, this is an elderly cohort of patients with extensive comorbidities and multiple revascularization procedures, and the relationship of any carcinomas to treatment in this age group with such comorbidities can never be precisely determined. At this time, there has been no increased incidence of malignancy with gene therapy, 7 but this issue deserves close observation in larger phase II and III placebo-controlled trials in which the true balance between safety and efficacy can be determined.
An interesting finding is that three patients in both the 2-and 4-mg dose cohort, experiencing net pain improvement, had diabetes or neuropathy, possibly suggesting some benefit in the neuropathic pain caused by diabetes or neuropathy. VM202 is not only a potent angiogenic and anti-apoptotic agent, 26, 27 but may also function as a neurotrophic factor, capable of promoting axonal growth and regeneration. 28 As loss of microvasculature in diabetes has also been implicated in acceleration of neuronal loss and pain symptoms, 29 VM202 may be an ideally suited candidate for the treatment of patients with diabetes or neuropathy. This observation is supported by a rat model in which investigators could demonstrate a significant decrease of pain and increase blood flow in sciatic nerve and hind paw of rats receiving HGF injections. 30 However, owing to the small sample size, this finding remains an observation only and will be closer evaluated in the phase II trial.
In conclusion, this first clinical trial in human using VM202 encoding dual isoforms of HGF is well tolerated and appears to be safe at doses as high as 16 mg with encouraging clinical results. These data support the performance of a phase II randomized, double-blind, placebo-controlled trial in patients with CLI using VM202, which started in April 2010.
MATERIALS AND METHODS
Study design
This was a prospective, open-label, dose-escalation, single-center study designed to assess the safety and tolerability of increasing doses of intramuscular injection of VM202 (ViroMed Co., Ltd, Seoul, Korea) in patients with CLI (http://www.clinicaltrials.gov; registration number: NCT00696124). A total of 12 patients (three per dose cohort) were enrolled to receive 2, 4, 8 or 16 mg of VM202. For each dose cohort, VM202 was administered as local intramuscular injections, with the first half of the dose administered at day 1 of the study and the second half administered at day 15. The primary intent was to investigate the safety and tolerability of VM202 intramuscular injections. Safety and clinical and physiological parameters of preliminary efficacy ABI, TBI, TCPO 2 , pain severity score by VAS and ulcer size) were evaluated at baseline and throughout follow-up. Adverse events were recorded throughout the 12 months follow-up.
Patient eligibility
Patients were considered for enrollment if they were from 20 to 90 years with CLI (Rutherford class 4 and 5), who were not candidates for surgical or percutaneous revascularization procedures because of comorbid conditions, failure of previous surgery or percutaneous interventions or because of failure of caliber of grafting arteries. Patients were required to have rest pain and/or ischemic ulcers or gangrene for a minimum of 4 weeks with a resting ankle systolic pressure p60 or resting toe systolic pressure p40 mm Hg and diagnostic angiography demonstrating a significant occlusion of the infrapopliteal arteries of the affected limb within the last 12 months. If not contraindicated, patients were asked to continue their anti-platelet and statin medication for the duration of the trial. Figure 3 Effect of plasmid DNA expressing two isoforms of HGF on visual analog scale (VAS) in 12 subjects separated by cohort. Pain severity score assessed by VAS shows a substantial pain reduction in the 2-mg cohort and an overall improvement at 6 months follow-up. Of note, no VAS score was available at 6 and 12 months for one subject in cohort 3 because of major amputation. *P¼0.03; baseline vs 6 months after VM202 injection. Figure 4 Effect of plasmid DNA expressing two isoforms of HGF on ulcer healing in 12 subjects. Ulcer healing was evaluated by the change of ulcer dimension since first ulcer onset. Ulcer dimension was classified as the expansion rate of ulcer (group 1: 450% increase of ulcer dimension, group 2: 1-50% increase of ulcer dimension, group 3: from 50 to 0% decrease of ulcer dimension, group 4: from 51 to 99% decrease of ulcer dimension, and group 5: complete healing). * P¼0.004; number of complete healed ulcers at 15 days after VM202 injection vs number of complete healed ulcers at 12 months after first VM202 injection. P¼0.015; 1 month vs 12 months, P¼0.006; 2 vs 12 months.
Exclusion criteria included severe CLI, which in the opinion of the investigators would require a major amputation within 4 weeks of study enrollment, estimated life expectancy of less than 6 months, hemodynamically significant aortoiliac occlusive disease, deep ulcerations with bone or tendon exposure, or clinical evidence of invasive infection (e.g., cellulitis, osteomyelitis). In addition, patients were excluded if they had undergone a successful revascularization procedure or sympathectomy within 12 weeks before study entry, had grade 3 or higher retinopathy, were on immunosuppressive medications, chemotherapy or radiation therapy or had evidence (clinical, laboratory or imaging) of malignant neoplasm, except for fully resolved basal cell carcinoma of the skin. Furthermore, patients were excluded if they have the following abnormal laboratory findings: hemoglobin o9 g dl À1 ; white blood count o3,000; platelet count o75 000; fasting glucose 4250 mg dl À1 ; aspartate transaminase and/or alanine transaminase 43Âupper limit of normal; human immunodeficiency virus; hepatitis B (HepBSAg); cytomegalovirus; hepatitis C.
The study was approved by the institutional review board and biosafety committee at Allina Health Systems for performance at Abbott Northwestern Hospital, Minneapolis, MN, USA. All patients gave written informed consent to participate in the study.
Materials
VM202 (pCK-HGF-X7) is a 7377-base pair plasmid DNA consisting of the mammalian expression vector, pCK, and a genomic cDNA hybrid of human hgf gene, HGF-X7. 12, 15, 31 The key feature of HGF-X7 is that it was designed by inserting the truncated intron 4 into the junction between exon 4 and exon 5 of hgf cDNA, so that both isoforms of HGF protein are expressed simultaneously and efficiently as in the human genome. 15 Because there is no change in the coding region of the hgf gene, HGF proteins generated from VM202 are identical to the wild-type human HGF proteins.
VM202 is supplied in a sterile glass vial containing 2 mg of lyophilized study product and is stored in a refrigerator at temperatures between 2 and 81C. Intramuscular injection was administered to the affected ischemic calf muscle at four to eight different injections sites chosen depending on the dose and the location of the occluded vessels. Each injection site was 2 cm apart from each other and each injection contained between 0.5 and 2 ml, depending on cohort assignment. Injection sites and treatment regimen is shown in Figure 5 .
Safety endpoints
The safety endpoints including adverse events, clinical chemistry and physical exam were obtained at baseline and during follow-up to 1 year. VM202 DNA concentration level was assessed at days 21 and 59, if detected at day 21. Change from baseline in serum HGF level was assessed at days 8, 15, 28 and 59, and neutralizing antibodies (anti-HGF antibodies) was assessed at days 15, 59 and 180. Patients were required to have American Cancer Society-recommended screening up to date. In addition, patients with a history of smoking received a chest computed tomography scan at baseline and at 12 months. Mandatory review of all safety data of each cohort was performed at 1-month follow-up by the data and safety monitoring board before enrollment in subsequent cohorts continued.
Secondary endpoints
Clinical outcome was assessed at 3, 6 and 12 months follow-up using ABI, TBI, TCPO 2 , VAS pain severity score and ulcer healing, and were compared with baseline. TCPO 2 measurement for limb perfusion was assessed using a TCPO 2 Radiometer (TCPO 2 , Radiometer TCM4 Series, 4 Channel, Copenhagen, Denmark). The sensor locations were predefined as anterolateral and posteromedial calf, dorsum of the foot and middle of the anterior chest wall as reference, and results were read after 10-15 min. TCPO 2 measurements at the dorsum of foot were used for this analysis, as it reflects the most severe areas of ischemia in patients with CLI. ABI and TBI were obtained at the affected limb by measuring both the posterior tibial and dorsalis pedis arteries for the ABI and the first toe digital artery for the TBI. A vessel with no detectable Doppler signal (presumed because of complete occlusion or a congenitally absent artery) was recorded as having a zero pressure. The highest obtainable pressure at the ankle level was used to calculate the ABI. At each study visit, the current pain intensity was quantified and compared with baseline using a 100-mm VAS in which 0 mm indicates no pain and 100 mm represents the most severe pain. All ulcers present at baseline visit and any new ulcers were documented by digital photography and ulcer sizes were measured with EZ graph. Ulcer healing was documented by ulcer size reduction in square millimeters throughout followup. Complete ulcer healing was defined as skin closure without drainage or dressing requirements. An ulcer area that has healed but reappeared and is unhealed at follow-up visit was considered not healed.
Statistical analysis
The small sample size and skewed distribution led to use of non-parametric statistical tests. Continuous variables are expressed as median and interquartile range. Categorical variables are expressed as frequencies and percentages. Wilcoxon signed-rank test was carried out to compare hemodynamic outcomes, including ABI, TBI, TCPO 2 , and pain severity score assessed by VAS at follow-up with baseline values. Data from the pharmacodynamics of HGF expression or the pharmacokinetics of VM202 plasmid in serum or whole blood were analyzed using the Kruskal-Wallis test and Wilcoxon signed-rank test. Ulcer healing was analyzed by Fisher's exact probability test. A P-value of o0.05 was considered statistically significant. Statistical analysis was performed using Stata/IC software version 10.1 (Stata/IC 10.1, Inc., College Station, TX, USA).
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